What sample types can be processed?
Our tests are designed to be performed on a range of processed histology and cytology specimens, including resections, Fine Needle Aspirates (FNAs), core biopsies etc. Generally these are received in the format of formalin-fixed paraffin-embedded (FFPE) blocks, although we are happy to also accept slides (stained/unstained) or curls pre-cut from such blocks, as well as air-dried or alcohol fixed direct smears from FNA samples or even pre-extracted DNA.
Please note that when submitting curls or extracted DNA, either a H&E stained slide must be submitted with the material or a pathologist must have reviewed the material prior to dispatch and confirmed that it meets our minimum assay requirements, see below. For somatic mutation requests, any cases where the tumour content cannot be verified prior to analysis will be returned untested.
How much is enough?
For virtually all of our tests, the relative proportion of tumour cells to nucleated non-tumour cells is the single most important sample characteristic. Requirements based upon physical amounts of tissue are of less value, as even large pieces of certain sample types (e.g. fat and blood) may contain very few nucleated cells. Alternatively, other sample types, like lymph nodes may be large with many tumour cells, but be so heavily infiltrated with normal lymphocytes that they do not reach the minimum relative tumour content. Nevertheless, as a very rough guide, a sample with a combined tumour area greater than 4 square millimetres that meets or exceed the minimum tumour contents specified below would be expected to be sufficient. However, even for samples which have been accepted on the basis of relative tumour content, the final decision upon whether to proceed with analysis will be based upon the quality and quantity of nucleic acid (DNA and/or RNA) recovered. Please note that there is no charge for rejected samples.
Multi-gene (NGS) tests require that tumour cells comprise >5% of all nucleated cells
Single-gene tests (KRAS, NRAS, BRAF & EGFR) require that tumour cells comprise >10% of all nucleated cells
MLH1 methylation & MSI analyses require regions where tumour cells comprise >20% of all nucleated cells, ideally (for MLH1) with additional non-involved regions for comparative purposes
Endopredict analysis requires regions where tumour comprises >30% by area (also see below)
For any samples received that are below the above cut offs, we will perform macro-dissection whenever possible in order to selectively harvest high tumour content sub-areas. However should this not be technically possible, samples will unfortunately have to be rejected and returned untested.
To avoid unnecessary sample rejection, we strongly suggest that either all available material is sent or that a pathologist reviews all such material locally first and selects that which is likely to yield the most DNA with the highest relative tumour content.
Please note: If sending more than a single sample per case, please ensure that you make it clear whether you wish us to select and analyse only the most suitable sample or analyse them all regardless. This will prevent results being delayed and/or analyses being charged incorrectly.
Endopredict specific comments
As this test is based on RNA expression rather than DNA sequencing, tumour requirements (>30%) are by area as opposed to the proportion nucleated cells. For eligibility, cases must also be ER+ve/HER2 -ve with known tumour size and not more than 3 positive lymph nodes. To avoid any unnecessary delays please provide a full histopathology report(s) with the specimen and completed request form.